Celldex Therapeutics, Inc. (CLDX)
NASDAQ: CLDX · Real-Time Price · USD
29.45
-0.15 (-0.51%)
At close: Dec 5, 2025, 4:00 PM EST
29.15
-0.30 (-1.02%)
After-hours: Dec 5, 2025, 5:58 PM EST
Celldex Therapeutics Employees
Celldex Therapeutics had 186 employees as of December 31, 2024. The number of employees increased by 26 or 16.25% compared to the previous year.
Employees
186
Change (1Y)
26
Growth (1Y)
16.25%
Revenue / Employee
$13,973
Profits / Employee
-$1,207,161
Market Cap
1.96B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CLDX News
- 25 days ago - Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer - GlobeNewsWire
- 4 weeks ago - Celldex to Present at Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Celldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spontaneous Urticaria Independent of Baseline Immunoglobulin E levels in Phase 2 Study at EADV Congress 2025 - GlobeNewsWire
- 3 months ago - Celldex Therapeutics, Inc. (CLDX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 3 months ago - Celldex to Present at Morgan Stanley 23rd Annual Global Healthcare Conference - GlobeNewsWire
- 3 months ago - Celldex: Despite Dropping Eosinophilic Esophagitis Program, Barzolvolimab On Track - Seeking Alpha
- 3 months ago - Celldex Therapeutics Pulls Plug On Eosinophilic Esophagitis Investigational Drug As Data Falls Short - Benzinga
- 3 months ago - Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE) - GlobeNewsWire